molecular design and synthesis of cyclized cytokines for biobetter development
| Project/Area Number |
23510273
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Living organism molecular science
|
|---|
| Research Institution | National Institute of Advanced Industrial Science and Technology |
|---|
Principal Investigator |
HONDA Shinya 独立行政法人産業技術総合研究所, バイオメディカル研究部門, 副研究部門長 (50344122)
|
|---|
| Project Period (FY) |
2011-04-28 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
|
|---|
| Keywords | 蛋白質 / 蛋白質工学 / バイオ医薬品 / バイオテクノロジー / 分子設計 |
|---|
| Outline of Final Research Achievements |
Aiming at the development of 'biobetter' medicines that are improved in metabolic stability than the cytokine proteins which had been already approved as pharmaceutical molecules, we synthesized new cyclic protein in which the both ends of its polypeptide backbone are connected to each other with amide bond and analyzed its functional and structural characteristics. As a result, receptor binding activity of the cyclized cytokine and its cell proliferation activity were found to be equal to a wild type cytokine. Moreover, it has been demonstrated that the thermal stability and protease tolerance are superior to the wild type. This shows that the molecule are promising a lead compound in drug discovery for new biologics.
|
Report
(3 results)
Research Products
(38 results)
